ADARx Pharmaceuticals, Inc. Form SCHEDULE 13D — Oct 5, 2026
SR One Capital Management and nine affiliated entities, including funds controlled by Dr. Simeon George, filed a Schedule 13D disclosing beneficial ownership of 9,936,661 shares of ADARx Pharmaceuticals common stock, equal to 9.3% of the class based on 106,801,325 shares outstanding as of September 28, 2026. The stake stems from pre-IPO preferred stock purchases totaling roughly $60 million across Series B, B-1 and C rounds, which converted to common stock at a 1-for-1.1717 ratio at the closing of ADARx's IPO on September 28, 2026; several funds also bought shares at the $17.00 IPO price.
Key figures
- Shares Outstanding
- 106801325
- Percent Of Class
- 9.3%
- Conversion Ratio
- 1-for-1.1717
- Greenshoe Shares
- 3937500
- Ipo Price Per Share
- 17
- Lockup Period Days
- 180
- Aggregate Shares Beneficially Owned
- 9936661
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.